The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1312
May 18, 2009
View Complete Issue         Table of Contents 2019 
Febuxostat (Uloric) for Chronic Treatment of Gout
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Febuxostat (Uloric) for Chronic Treatment of Gout
May 18, 2009 (Issue: 1312)
Febuxostat (Uloric - Takeda), a xanthine oxidase inhibitor, has been approved by the FDA for chronic management of hyperuricemia in patients with gout. It is the first drug marketed for treatment of gout in 40 years. Febuxostat is structurally...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Febuxostat (Uloric) for Chronic Treatment of Gout
Article code: 1312a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.